NEW YORK (GenomeWeb News) – Horizon Discovery has licensed human genetic modeling technology for use in cancer research from Italy's University of Torino Medical School, the company said today.
The firm will pay the university undisclosed fees for sub-licensing control of the related patent estate.
The patented technology, developed at Torino's Department of Oncological Sciences, is related to the use of panels of engineered isogenic human cell lines that model genetic mutations found in cancer patients.
The company, which is based at the Babraham Research Campus in Cambridge, UK, and has facilities in Torino, said that the inventions covered under the patent will be used in its existing and new service programs.
Horizon CEO Chris Torrance said in a statement that the new intellectual property covers the use of endogenous gene-targeted human disease models using homologous recombination methodologies for personalized drug discovery. It may be used in clinical trial selection and identification of drug-combination therapies for inherited or acquired genetic-based patient resistance, Torrance said.
In the future, Torrance said, all of the company's X-MAN products and screening services will receive "an extended license to employ these new inventions."
Professor Alberto Bardelli, of Torino's Department of Oncological Sciences, said that the X-MAN models "will have a key role in defining new drug sensitivity and resistance mechanisms as well as finding rational combination therapies that reverse resistance for testing in the clinic."
Financial terms of the agreement were not released.